![Comparative economic study of the use of corifollitropin alfa and daily rFSH for controlled ovarian stimulation in older patients: Cost-minimization analysis based on the PURSUE study - ScienceDirect Comparative economic study of the use of corifollitropin alfa and daily rFSH for controlled ovarian stimulation in older patients: Cost-minimization analysis based on the PURSUE study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2405661818300029-t1.jpg)
Comparative economic study of the use of corifollitropin alfa and daily rFSH for controlled ovarian stimulation in older patients: Cost-minimization analysis based on the PURSUE study - ScienceDirect
![Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study | Reproductive ... Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study | Reproductive ...](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12958-020-00610-2/MediaObjects/12958_2020_610_Fig1_HTML.png)
Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study | Reproductive ...
![PDF) Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: A phase 3 open-label follow-up to Main Study PDF) Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: A phase 3 open-label follow-up to Main Study](https://www.researchgate.net/publication/303909646/figure/fig2/AS:487400284659713@1493216691774/Patient-Disposition_Q320.jpg)